RLMD
Price:
$2.8
Market Cap:
$84.49M
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.[Read more]
Industry
Biotechnology
IPO Date
2014-06-20
Stock Exchange
NASDAQ
Ticker
RLMD
According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 83.00M. This represents a change of -26.72% compared to the average of 113.26M of the last 4 quarters.
The mean historical Enterprise Value of Relmada Therapeutics, Inc. over the last ten years is 154.68M. The current 83.00M Enterprise Value has changed 5.27% with respect to the historical average. Over the past ten years (40 quarters), RLMD's Enterprise Value was at its highest in in the September 2022 quarter at 1.07B. The Enterprise Value was at its lowest in in the December 2017 quarter at 4.86M.
Average
154.68M
Median
88.35M
Minimum
8.47M
Maximum
497.61M
Discovering the peaks and valleys of Relmada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 772.74%
Maximum Annual Enterprise Value = 497.61M
Minimum Annual Increase = -76.85%
Minimum Annual Enterprise Value = 8.47M
Year | Enterprise Value | Change |
---|---|---|
2023 | 120.52M | 22.97% |
2022 | 98.01M | -72.08% |
2021 | 351.02M | -29.46% |
2020 | 497.61M | 53.70% |
2019 | 323.76M | 772.74% |
2019 | 37.10M | 177.39% |
2018 | 13.37M | 57.95% |
2017 | 8.47M | -53.53% |
2016 | 18.22M | -76.85% |
2015 | 78.70M | 149.88% |
The current Enterprise Value of Relmada Therapeutics, Inc. (RLMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
189.85M
5-year avg
278.18M
10-year avg
154.68M
Relmada Therapeutics, Inc.’s Enterprise Value is less than Cytokinetics, Incorporated (6.54B), less than DICE Therapeutics, Inc. (1.82B), less than Edgewise Therapeutics, Inc. (3.01B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (2.51B), less than Third Harmonic Bio, Inc. (269.19M), greater than PMV Pharmaceuticals, Inc. (47.77M), less than Enochian Biosciences, Inc. (85.97M), less than Revolution Medicines, Inc. (9.43B), greater than Pardes Biosciences, Inc. (75.90M), greater than Shattuck Labs, Inc. (6.89M), less than Eliem Therapeutics, Inc. (119.64M), greater than Champions Oncology, Inc. (66.07M), less than Century Therapeutics, Inc. (104.89M), less than Fusion Pharmaceuticals Inc. (1.87B), less than Bicycle Therapeutics plc (537.81M), greater than RAPT Therapeutics, Inc. (4.97M), less than NewAmsterdam Pharma Company N.V. (1.37B), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than Nuvation Bio Inc. (923.54M), greater than Magenta Therapeutics, Inc. (-114170976.00), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Graphite Bio, Inc. (-15007658.00),
Company | Enterprise Value | Market cap |
---|---|---|
6.54B | $5.79B | |
1.82B | $2.27B | |
3.01B | $3.05B | |
12.43B | $12.60B | |
2.51B | $3.02B | |
269.19M | $561.88M | |
47.77M | $83.31M | |
85.97M | $45.38M | |
9.43B | $9.55B | |
75.90M | $135.19M | |
6.89M | $47.98M | |
119.64M | $342.68M | |
66.07M | $61.85M | |
104.89M | $102.89M | |
1.87B | $1.83B | |
537.81M | $1.42B | |
4.97M | $37.75M | |
1.37B | $1.87B | |
-20511738.00 | $108.71M | |
923.54M | $942.39M | |
-114170976.00 | $42.44M | |
-6333315.00 | $8.20M | |
-15007658.00 | $185.19M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Relmada Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Relmada Therapeutics, Inc. (RLMD)?
What is the 3-year average Enterprise Value for Relmada Therapeutics, Inc. (RLMD)?
What is the 5-year average Enterprise Value for Relmada Therapeutics, Inc. (RLMD)?
How does the current Enterprise Value for Relmada Therapeutics, Inc. (RLMD) compare to its historical average?